Cármino Antônio De Souza

Research interests

Publications

• Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30685-5

• Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

  British Journal of Haematology · 2014 · https://doi.org/10.1111/bjh.13108

• Improvement in the outcome of invasive fusariosis in the last decade

  Clinical Microbiology and Infection · 2013 · https://doi.org/10.1111/1469-0691.12409

• Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

  Blood · 2013 · https://doi.org/10.1182/blood-2013-06-510396

• Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil

  Clinical Microbiology and Infection · 2012 · https://doi.org/10.1111/1469-0691.12002

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70201-7

• Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2007.14.3339

• Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.25.3724

• Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

  Blood · 2007 · https://doi.org/10.1182/blood-2006-09-046839

• Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients

  Bone Marrow Transplantation · 2007 · https://doi.org/10.1038/sj.bmt.1705677

• Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection

  Cancer · 2003 · https://doi.org/10.1002/cncr.11510

• A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies

  Bone Marrow Transplantation · 1998 · https://doi.org/10.1038/sj.bmt.1701510

• VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

  Journal of Clinical Oncology · 1998 · https://doi.org/10.1200/jco.1998.16.8.2796

Current projects

No projects listed.